University of North Carolina, Greensboro, USA.
J Law Med Ethics. 2010 Winter;38(4):840-6. doi: 10.1111/j.1748-720X.2010.00537.x.
Most codes of research ethics and the practice of Institutional Review Boards (IRBs) allow human subjects to withdraw from research at any time. Consent forms invariably make a statement to this effect. So understood, a subject's right to withdraw from research is inalienable; she cannot, through her consent, surrender this right. Recently critics have argued that in selected circumstances the right to withdraw from research is alienable; subjects have the moral authority, through their consent, to obligate themselves not to withdraw. Two kinds of cases have been cited to support this. In one case, there will be great benefits lost if subjects are permitted to withdraw before the completion of the protocol. In the other case, there will be harm to third parties if subjects withdraw from the experiment. In this paper, I defend the inalienability of the right to withdraw from research. I argue, first, that securing the desired benefits and avoiding the feared harms can be achieved without allowing waiver. Second, I show that permitting waiver in these cases does not guarantee that the ends sought will be achieved. And third, I articulate positive reasons for conceiving subjects' right to withdraw from research as inalienable.
大多数研究伦理规范和机构审查委员会(IRB)的实践都允许人类受试者在任何时候退出研究。知情同意书通常会对此作出声明。从这个意义上说,受试者有权退出研究是不可剥夺的;她不能通过同意放弃这项权利。最近,批评者认为,在某些情况下,退出研究的权利是可转让的;通过同意,受试者有道德权威来约束自己不退出。有两种情况被引用来说明这一点。在一种情况下,如果允许受试者在协议完成之前退出,将会失去巨大的利益。在另一种情况下,如果受试者从实验中退出,将会对第三方造成伤害。在本文中,我为退出研究的权利的不可转让性进行辩护。我首先认为,在不允许弃权的情况下,可以实现确保预期利益和避免恐惧危害的目标。其次,我表明,在这些情况下允许弃权并不能保证所寻求的目标能够实现。第三,我阐明了将受试者退出研究的权利视为不可剥夺的积极理由。